The Global Patient-Reported Outcome Measure (G-PROM) quantifies and compares the distribution of patients’ overall experiences on medi-cations based on trajectory mapping. To inform the trajectory mapping, study authors surveyed participants with RA from the ArthritisPower research registry (n=195) who compared an adverse event (AE) as worse, better, or no better or worse than a referent AE. These data al-lowed for the construction of a rank ordering of “equivalence classes,” or groups of AEs judged by participants as having a comparable impact on quality of life. A subsequent survey of ArthritisPower participants with RA (n=426), with similar demographic characteristics, were asked to indicate their preference for pairs of outcomes, where each outcome include both a specified level of benefit [little or no improvement, some improvement, and major improvement] and an AE. Participants’ ratings generated a 5-level hierarchy of global outcomes. With further valida-tion, study authors predict that G-PROM will enable randomized con-trolled trials to report the percentage of patients classified into each level; thus, providing patients and their rheumatologists with a much clearer understanding of the range and likelihood of the total effects of competing treatment options on their quality of life.
A Note From Dr. Liana Fraenkel
I am very excited about this opportunity to partner with FHI. My research career has focused on patient centered approaches to improving the quality of decisions that patients with rheumatic diseases make with their rheumatologists in day to day practice. Many of our research studies have been developed based on specific questions raised by patients. Our most recent study came about to address patients’ requests to have information that describes the global experience that patients have on specific medications. Until now, clinical trials have reported benefits separately from side effects, so it is difficult for patients and doctors to know how patients are likely to feel overall on a new medication. We have created a new measure called G-PROM (Global Patient-Reported Outcome Measure), that reports the percentage of patients who simultaneously experience specific levels of both improvements in symptoms and side effects such as nausea or infections. Using G-PROM, we hope that patients will be able to understand the likely trade-offs between benefits and risks for different treatments, helping them to have more confidence that their medication choice aligns with their personal preferences. Partnering with FHI will enable us to see how G-PROM performs in actual clinical practice. We are grateful that FHI is able to support research focused on improving the quality care and ultimately the well-being of the millions of patients with chronic rheumatic illness.
Adjunct Professor of Medicine
Yale University School of Medicine
Director, Patient Centered Population Health Services
Berkshire Health Systems